UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,014 shares of the company’s stock after selling 7,872 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.07% of Arcus Biosciences worth $923,000 at the end of the most recent quarter. Several other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock valued at $506,000 after buying an additional 833 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Arcus Biosciences by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock worth $223,000 after acquiring an additional 2,410 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Arcus Biosciences by 11.2% during the 4th quarter. Handelsbanken Fonder AB now owns 24,800 shares of the company’s stock worth $369,000 after acquiring an additional 2,500 shares during the period. MetLife Investment Management LLC grew its holdings in Arcus Biosciences by 8.1% in the 4th quarter. MetLife Investment Management LLC now owns 33,525 shares of the company’s stock valued at $499,000 after buying an additional 2,521 shares in the last quarter. Finally, WINTON GROUP Ltd grew its holdings in Arcus Biosciences by 5.4% in the 4th quarter. WINTON GROUP Ltd now owns 72,310 shares of the company’s stock valued at $1,077,000 after buying an additional 3,730 shares in the last quarter. Institutional investors own 92.89% of the company’s stock. Arcus Biosciences Trading Up 1.9% NYSE:RCUS opened at $10.04 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -3.19 and a beta of 0.83. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98. The business has a fifty day moving average price of $8.51 and a 200-day moving average price of $11.36. Arcus Biosciences (NYSE:RCUS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $28.00 million during the quarter, compared to analysts’ expectations of $38.61 million. During the same quarter in the previous year, the company posted ($0.05) EPS. The company’s quarterly revenue was down 80.7% on a year-over-year basis. Sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current year. Analysts Set New Price Targets A number of research firms have recently commented on RCUS. The Goldman Sachs Group lowered their price target on Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. Wells Fargo & Company decreased their price target on Arcus Biosciences from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Morgan Stanley cut their target price on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. Finally, Barclays cut their price target on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating on the stock in a report on Wednesday, April 23rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Arcus Biosciences has an average rating of “Moderate Buy” and a consensus target price of $24.13. View Our Latest Research Report on RCUS Arcus Biosciences Profile (Free Report) Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

06/11/2025

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 8,400 shares of the Company's common stock at an exercise price per share of $9.85, which was the closing price on June 9, 2025, and restri.

06/10/2025